NCT03954470 (FAIR-PROGRESS) is a clinical trial in Chronic Kidney Disease stage4, sponsored by Centre Hospitalier Universitaire de Besancon.

Who is sponsoring NCT03954470?

NCT03954470 is sponsored by Centre Hospitalier Universitaire de Besancon.

What condition does NCT03954470 study?

NCT03954470 studies Chronic Kidney Disease stage4.

Is NCT03954470 still recruiting?

NCT03954470 is currently completed. Last updated 17 May 2019.

Last reviewed 2019-05-17 · How we verify

NCT03954470: FAIR-PROGRESS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Factors Influencing Risk of Progression of Chronic Kidney Disease

Completed Last updated 17 May 2019

What this trial tests

trial in Chronic Kidney Disease stage4 in 1,300 participants. Completed in 31 December 2018.

Timeline

9 April 2012

Primary endpoint
31 December 2018

31 December 2018

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Besancon
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,300
Start date	9 April 2012
Primary completion	31 December 2018
Estimated completion	31 December 2018
Sites	1 location across France

Conditions studied

Chronic Kidney Disease stage4 — all drugs for Chronic Kidney Disease stage4 →

Sponsor

Centre Hospitalier Universitaire de Besancon

Who can join

18 and older, any sex, with Chronic Kidney Disease stage4. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to identify typical patterns of renal function evolution in patients with stage 4 chronic kidney disease, regularly followed in nephrology consultation and included in a French cohort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Kidney Disease stage4

Currently open trials in the same condition.

NCT07309094 — Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD · recruiting

Other Centre Hospitalier Universitaire de Besancon trials

Trials by the same sponsor.

NCT07492199 — High Depth Exome Sequencing on DNA From a Salivary Sample by Mouth Smear. · not yet recruiting
NCT07438015 — VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit · NA · not yet recruiting
NCT06796114 — Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du · NA · recruiting
NCT06864065 — Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder · NA · recruiting
NCT07067762 — Botulinum Toxin Injections Into the Salivary Glands of Cerebrospinal Children With Chronic Sialorrhea · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03954470 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Besancon
Last refreshed: 17 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03954470.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing